Yahoo · Oct 30, 2026
Is 50% Crash Risk For Iovance Stock Real?
For questions about this article or underlying research, email [email protected].
NASDAQ · VRTX
Vertex Pharmaceuticals Incorporated
Healthcare · Biotechnology
$558.88
Up+$18.88 (+3.50%)
Updated Oct 31, 2026, 5:03 PM
SID Score
6.3/10
Composite research score
Smart Money
48/100
Neutral
- Market cap
- 114.46B
- P/E ratio
- 31.02
- Dividend yield
- 0.00%
- 52-week range
- $412.27 – $563.80
- Volume
- 3.04M
- Avg. volume
- 1.51M
Price performance · VRTX
VRTX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
VRTX closed at $558.88 after 21 trading sessions, up 10.73% for the selected period.
- Last close
- $558.88
- Period change
- +10.73%
- Period low
- $485.22
- Period high
- $558.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $550.73 | $563.7995 | $549.89 | $558.88 | 3.04M |
| Oct 29, 2026 | $536.46 | $546.61 | $534.01 | $540.00 | 1.54M |
| Oct 28, 2026 | $514.45 | $534.94 | $513.37 | $529.69 | 1.28M |
| Oct 27, 2026 | $514.835 | $521.43 | $509.205 | $521.03 | 1.02M |
| Oct 26, 2026 | $526.86 | $529.66 | $509.33 | $517.49 | 1.19M |
| Oct 23, 2026 | $531.66 | $533.08 | $522.91 | $523.93 | 832.63K |
| Oct 22, 2026 | $527.18 | $537.81 | $521.295 | $535.17 | 1.64M |
| Oct 21, 2026 | $512.79 | $528.57 | $510.48 | $524.52 | 1.45M |
| Oct 20, 2026 | $507.89 | $515.735 | $505.00 | $514.65 | 1.23M |
| Oct 19, 2026 | $500.00 | $505.83 | $499.50 | $501.95 | 1.3M |
| Oct 16, 2026 | $511.06 | $512.21 | $497.4935 | $499.74 | 1.41M |
| Oct 15, 2026 | $514.91 | $517.6795 | $507.21 | $508.75 | 2.26M |
| Oct 14, 2026 | $490.45 | $502.935 | $487.54 | $498.50 | 2.09M |
| Oct 13, 2026 | $507.55 | $508.57 | $484.08 | $485.22 | 1.19M |
| Oct 12, 2026 | $512.44 | $514.80 | $506.00 | $507.00 | 952.75K |
| Oct 9, 2026 | $502.11 | $514.90 | $502.06 | $510.08 | 1.48M |
| Oct 8, 2026 | $503.14 | $507.87 | $498.90 | $503.25 | 1.49M |
| Oct 7, 2026 | $504.075 | $511.505 | $503.942 | $505.64 | 806.84K |
| Oct 6, 2026 | $505.00 | $507.41 | $496.325 | $502.31 | 775.07K |
| Oct 5, 2026 | $504.78 | $506.01 | $496.15 | $503.50 | 915.14K |
| Oct 2, 2026 | $509.50 | $509.50 | $499.95 | $504.73 | 939.66K |
Latest VRTX news
The latest Smart Investors Daily articles mentioning VRTX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VRTX research
Overview
Company profile and research snapshot.
Company profile
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $483.00
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 28, 2026 | UBS | Buy | — |
| Sep 11, 2026 | JP Morgan | Overweight | — |
| Sep 2, 2026 | Morgan Stanley | Overweight | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 30, 2026
Why Did Insmed Stock Jump?
For questions about this article or underlying research, email [email protected].
ChartMill · Oct 29, 2026
After-Hours S&P 500 Movers: Mondelez and FedEx Freight Gain, Intel and Reddit Fall
S&P 500 after-hours movers: Mondelez International and FedEx Freight were among gainers, while Intel and Reddit were among decliners after today's U.S. session.
Benzinga · Oct 29, 2026
Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 4.68% on an annualized basis producing an average annual return of 13.63%. Currently, Vertex Pharmaceuticals has a market
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
